Heterogeneity of ER, PR, HER2, and Ki67 were present in 24.0% MMBC, which was associated with more adjuvant endocrine therapy usage (p = 0.046) and shorter DFS (p = 0.041), indicating the necessity of molecular assessments for different tumor foci in patients with MMBC. This evidence concerns the gene MKI67 and neoplasm.